EDIT – editas medicine, inc. (US:NASDAQ)

DELAYED


Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low


VWAP
Today’s Volatility
20 Days Volatility
Open
Prior Close

YTD

1 Day

EDIT

SPY

QQQ

Swipe to see more

Main News & Impact Reports

Date

Time

Symbol

Headline

Impact

11/25

08:02 am

edit

Editas Medicine, Inc. (NASDAQ: EDIT) was downgraded by analysts at Bank of America Co. from a "buy" rating to an "underperform" rating. They now have a $1.00 price target on the stock, down previously from $13.00.

Medium Report

Report

11/6

01:02 pm

edit

Editas Medicine, Inc. (NASDAQ: EDIT) was upgraded by analysts at Evercore ISI from an "in-line" rating to an "outperform" rating.

Low Report

Editas Medicine, Inc. (NASDAQ: EDIT) was upgraded by analysts at Evercore ISI from an "in-line" rating to an "outperform" rating.

Report

11/6

09:00 am

edit

Editas Medicine to Participate in Upcoming Investor Conferences

Low Report

Editas Medicine to Participate in Upcoming Investor Conferences

Report

11/6

07:21 am

edit

Growth Investors: Industry Analysts Just Upgraded Their Editas Medicine, Inc. (NASDAQ:EDIT) Revenue Forecasts By 19% [Yahoo! Finance]

Medium Report

Growth Investors: Industry Analysts Just Upgraded Their Editas Medicine, Inc. (NASDAQ:EDIT) Revenue Forecasts By 19% [Yahoo! Finance]

Report

11/5

05:34 pm

edit

Editas Medicine, Inc. (NASDAQ: EDIT) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $12.00 price target on the stock.

Medium Report

Editas Medicine, Inc. (NASDAQ: EDIT) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $12.00 price target on the stock.

Report

11/5

01:04 pm

edit

Editas Q3 Loss Narrower Than Expected, Revenues Decrease Y/Y [Yahoo! Finance]

Low Report

Editas Q3 Loss Narrower Than Expected, Revenues Decrease Y/Y [Yahoo! Finance]

Report

11/5

11:36 am

edit

Editas Medicine, Inc. (NASDAQ: EDIT) had its price target lowered by analysts at Royal Bank of Canada from $8.00 to $5.00. They now have a "sector perform" rating on the stock.

Low Report

Editas Medicine, Inc. (NASDAQ: EDIT) had its price target lowered by analysts at Royal Bank of Canada from $8.00 to $5.00. They now have a "sector perform" rating on the stock.

Report

11/5

11:19 am

edit

Editas Medicine, Inc. (NASDAQ: EDIT) had its price target lowered by analysts at Stifel Nicolaus from $17.00 to $11.00. They now have a "buy" rating on the stock.

Low Report

Editas Medicine, Inc. (NASDAQ: EDIT) had its price target lowered by analysts at Stifel Nicolaus from $17.00 to $11.00. They now have a "buy" rating on the stock.

Report

Date

Time

Symbol

Company Name

Action

%Chg

11/4/2024

07:30 am

EDIT

editas medicine, inc.

BEAT Report

-1.4%

editas medicine, inc.

Report

8/7/2024

07:00 am

EDIT

editas medicine, inc.

MISS Report

-10.1%

editas medicine, inc.

Report

5/8/2024

07:00 am

EDIT

editas medicine, inc.

MISS Report

-10.1%

editas medicine, inc.

Report

2/28/2024

07:00 am

EDIT

editas medicine, inc.

BEAT Report

24.5%

editas medicine, inc.

Report

Date

Time

Action

From

Firm

Impact

%Chg

11/6

01:02 pm

Upgrades

In-line

Outperform

Evercore ISI

Low

Report

-3.0%

Report

11/6

01:02 pm

Upgrades

In-line

Outperform

Evercore ISI

Low

Report

-3.0%

Report

11/5

05:34 pm

Reiterates

Buy

Chardan Capital

Medium

Report

6.8%

Report

11/5

05:22 pm

Maintains

Buy

Chardan Capital

Medium

Report

5.1%

Report

11/5

11:32 am

Maintains

Sector Perform

RBC Capital

Low

Report

-0.8%

Report

11/5

11:32 am

Maintains

Sector Perform

RBC Capital

Low

Report

-0.8%

Report

11/5

10:55 am

Maintains

Buy

Stifel

Low

Report

2.3%

Report

11/5

10:22 am

Maintains

Overweight

Wells Fargo

Medium

Report

5.8%

Report

Date

Time

Symbol

Headline

Impact

11/12

02:30 pm

edit

Form SC 13G/A Editas Medicine, Inc. Filed by: VANGUARD GROUP INC

Neutral Report

Form SC 13G/A Editas Medicine, Inc. Filed by: VANGUARD GROUP INC

Report

11/4

11:57 am

edit

Form SC 13G/A Editas Medicine, Inc. Filed by: VANGUARD GROUP INC

Medium Report

Form SC 13G/A Editas Medicine, Inc. Filed by: VANGUARD GROUP INC

Report

11/4

07:37 am

edit

Form 10-Q Editas Medicine, Inc. For: Sep 30

Low Report

Form 10-Q Editas Medicine, Inc. For: Sep 30

Report

11/4

07:33 am

edit

Form 8-K Editas Medicine, Inc. For: Nov 04

Low Report

Form 8-K Editas Medicine, Inc. For: Nov 04

Report

10/22

07:05 am

edit

Form 8-K Editas Medicine, Inc. For: Oct 22

High Report

Form 8-K Editas Medicine, Inc. For: Oct 22

Report

10/17

01:11 pm

edit

Form SC 13G/A Editas Medicine, Inc. Filed by: STATE STREET CORP

Low Report

Form SC 13G/A Editas Medicine, Inc. Filed by: STATE STREET CORP

Report

10/4

06:01 am

edit

Form 8-K Editas Medicine, Inc. For: Oct 03

Medium Report

Form 8-K Editas Medicine, Inc. For: Oct 03

Report

9/6

04:21 pm

edit

Form 4 Editas Medicine, Inc. For: Sep 04 Filed by: Mei Baisong

Low Report

Form 4 Editas Medicine, Inc. For: Sep 04 Filed by: Mei Baisong

Report

Stock Stats

News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings

Order Stats
Sub-Penny

Odd lot

Avg. bid-ask spread

Avg. bid-ask size

Shares at ask/bid

Off exchange

Main News & Impact Reports

Don’t Miss Out On The Next BIG Stock Move

Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.